picoplatin picoplatin picoplatin is a platinum-based antineoplastic agent in clinical development by poniard pharmaceuticals (previously neorx) for the treatment of patients with solid tumors. picoplatin names iupac name azane; 2-methylpyridine; platinum(2+); dichloride identifiers cas number 181630-15-9 y 3d model (jsmol) ionic form: interactive imagecoordination form: interactive image chemspider 154428 n echa infocard 100.205.233 pubchem cid 177358 unii b5tan0l720 y comptox dashboard (epa) dtxsid10939458 inchi inchi=1s/c6h7n.2clh.h3n.pt/c1-6-4-2-3-5-7-6;;;;/h2-5h,1h3;2*1h;1h3;/q;;;;+2/p-2 nkey: iimioebmyprqgu-uhfffaoysa-l ninchi=1/c6h7n.2clh.h3n.pt/c1-6-4-2-3-5-7-6;;;;/h2-5h,1h3;2*1h;1h3;/q;;;;+2/p-2key: iimioebmyprqgu-nuqvwonbag smiles ionic form: cc1ccccn1.n...coordination form: cl(cl)()1ccccc1c properties chemical formula c6h10cl2n2pt molar mass 376.14 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references in phase i and phase ii clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer. however, in phase iii trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer. hopes are now pinned on its use for metastatic colorectal cancer.